Taysha Gene Therapies (TSHA) Misses Q4 EPS by 58c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($0.99), $0.58 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $10 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities
• Alimentation Couche-Tard Inc (ATD/B:CN) (ANCUF) PT Raised to Cdn$104 at UBS